Medical Ethics | Penn Today

The Washington Post

Med schools should de-emphasize standardized admissions tests

In a cowritten Op-Ed, College of Arts and Sciences student Cameron Sabet urges medical schools to make their standardized tests pass/fail in order to remove barriers for disadvantaged minority applicants.

Diverse: Issues in Higher Education

A dynamic thinker

A profile examines the career of Anita L. Allen of Penn Carey Law and the School of Arts & Sciences, who was recently named as one of two recipients of the Hastings Center’s 2022 Bioethics’ Founders Award.

Tackling the ethical considerations of dementia research

Alzheimer’s research poses tricky questions. Bedside-nurse-turned-bioethicist Emily Largent wants to answer them, and to improve the lives of Alzheimer’s patients.

Going beyond the binary in historical explorations of sex and gender

Beans Velocci of the School of Arts & Sciences explores how sex and gender have been shaped and categorized through history—and the consequences of those constructions taking on the guise of scientific and medical fact.

Bloomberg

Preterm birth drug Makena ignites argument over health equity

Holly Fernandez Lynch of the Perelman School of Medicine says that there needs to be a truly expedited pathway for withdrawal once a drug is deemed unfit for the market.

Five researchers newly elected to National Academy of Medicine: Regina Cunningham, Elizabeth Howell, Steven Joffe, Katalin Karikó, and Drew Weissman

Five from Penn elected to National Academy of Medicine

Five Penn experts have been elected to the National Academy of Medicine for their contributions to the advancement of the medical sciences, health care, and public health.

STAT News

How can the latest Alzheimer’s therapy reach patients? Follow this trustworthy process

In an op-ed, Jason Karlawish of the Perelman School of Medicine outlines the reliable process required to properly evaluate the effects of lecanemab, a new Alzheimer’s drug already approved by the FDA.

Bloomberg

Biogen’s next Alzheimer drug feeds push for FDA approval revamp

Emily Largent and Holly Fernandez Lynch of the Perelman School of Medicine are quoted about the clinical uncertainty of new Alzheimer’s drug findings and the FDA’s need to have post-approval trials underway.

NPR

FDA seems poised to approve a new drug for ALS, but does it work?

Holly Fernandez Lynch of the Perelman School of Medicine says that the FDA’s current trajectory has been characterized by increased willingness to accept weaker evidence.

Abortion clinic websites may unwittingly aid patient prosecutions

More than 99% of abortion clinic web pages studied included widely used code that transferred user data to external entities, which could sell the data or provide it to law enforcement, without the clinics knowledge.

Filters